An Observational Study of Avastin (Bevacizumab) in Patients With Metastatic Colorectal Cancer (ACORN)
NCT ID: NCT01506167
Last Updated: 2018-05-14
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
719 participants
OBSERVATIONAL
2012-07-06
2017-03-10
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A Study of Avastin (Bevacizumab) Plus Crossover Fluoropyrimidine-Based Chemotherapy in Patients With Metastatic Colorectal Cancer.
NCT00700102
A Study of Avastin With Chemotherapy for Treatment of Metastatic or Advanced and Unresectable Colorectal Adenocarcinoma
NCT00097578
Observation of Patients With Metastatic Colorectal Cancer Starting Chemotherapy Combined With Bevacizumab (Avastin)
NCT02612077
Avastin (Bevacizumab) in the Treatment of Metastatic Colorectal Cancer in Normal Clinical Use in the UK Population
NCT02542436
A Study of Avastin (Bevacizumab) in Combination With mFOLFOX-6 or FOLFOXIRI in Patients With Metastatic Colorectal Cancer.
NCT00778102
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
COHORT
PROSPECTIVE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Bevacizumab and Capecitabine/Oxaliplatin
Participants who receive bevacizumab in combination with capecitabine/oxaliplatin
Bevacizumab
Bevacizumab was administered as part of standard first-line treatment
Capecitabine/Oxaliplatin
Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Bevacizumab and Fluorouracil/Folinic Acid/Oxaliplatin
Participants who receive bevacizumab in combination with fluorouracil/folinic acid/oxaliplatin
Bevacizumab
Bevacizumab was administered as part of standard first-line treatment
Fluorouracil/Folinic Acid/Oxaliplatin
Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Bevacizumab and Capecitabine
Participants who receive bevacizumab in combination with capecitabine
Bevacizumab
Bevacizumab was administered as part of standard first-line treatment
Capecitabine
Capecitabine was administered along with bevacizumab as part of standard first-line treatment
Bevacizumab and Fluorouracil/Folinic Acid/Irinotecan
Participants who receive bevacizumab in combination with fluorouracil/folinic acid/irinotecan
Bevacizumab
Bevacizumab was administered as part of standard first-line treatment
Fluorouracil/Folinic Acid/Irinotecan
Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
Bevacizumab and Capecitabine/Irinotecan
Participants who receive bevacizumab in combination with capecitabine/irinotecan
Bevacizumab
Bevacizumab was administered as part of standard first-line treatment
Bevacizumab and Fluorouracil +/- Folinic Acid
Participants who receive bevacizumab in combination with fluorouracil +/- folinic acid
Bevacizumab
Bevacizumab was administered as part of standard first-line treatment
Fluorouracil +/- Folinic Acid
Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
Other
Participants who receive bevacizumab in combination with other first-line chemotherapy regimens
Bevacizumab
Bevacizumab was administered as part of standard first-line treatment
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Bevacizumab
Bevacizumab was administered as part of standard first-line treatment
Capecitabine/Oxaliplatin
Capecitabine/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Fluorouracil/Folinic Acid/Oxaliplatin
Fluorouracil/folinic acid/oxaliplatin were administered along with bevacizumab as part of standard first-line treatment
Capecitabine
Capecitabine was administered along with bevacizumab as part of standard first-line treatment
Fluorouracil/Folinic Acid/Irinotecan
Fluorouracil/folinic acid/irinotecan were administered along with bevacizumab as part of standard first-line treatment
Fluorouracil +/- Folinic Acid
Fluorouracil +/- folinic acid were administered along with bevacizumab as part of standard first-line treatment
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Receiving Avastin in combination with a first-line standard of care chemotherapy regimen
* Avastin initiated at the same time as first-line chemotherapy regimen
Exclusion Criteria
* Contraindication to Avastin
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Hoffmann-La Roche
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Clinical Trials
Role: STUDY_DIRECTOR
Hoffmann-La Roche
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Royal United Hospital Bath; Diabetes and Lipid Research, Wolfson Centre
Bath, , United Kingdom
Wexham Park Hospital; Oncology
Berkshire, , United Kingdom
Queen Elizabeth Hospital
Birmingham, , United Kingdom
Birmingham Heartlands Hospital; Dept of Oncology
Birmingham, , United Kingdom
Bishop Auckland Hospital;Oncology Department
Bishop Auckland, , United Kingdom
University Hospital of North Staffordhire
Blackpool, , United Kingdom
Bradford Royal Infirmary; Dept of Medical Oncology C/O Ward15
Bradford, , United Kingdom
Bristol Haematology and Oncology Centre
Bristol, , United Kingdom
West Suffolk Hospital Nhs Trust; Gi Corridor
Bury St Edmunds, , United Kingdom
Kent & Canterbury Hospital
Canterbury, , United Kingdom
Cumberland Infirmary; Oncology Department
Carlisle, , United Kingdom
Broomfield Hospital; Oncology
Chelsmford, , United Kingdom
University Hospital North Tees
Cleveland, , United Kingdom
Castle Hill Hospital; Academic Oncology
Cottingham, , United Kingdom
Darlington Memorial Hospital
Darlington, , United Kingdom
Russells Hall Hospital; Dept of Hematology
Dudley, , United Kingdom
University Hospital of North Durham; Oncology
Durham, , United Kingdom
Harrogate Hospital
Harrogate, , United Kingdom
Northhwick Park Hospital;Oncology Department
Harrow, , United Kingdom
Ipswich Hospital; Oncology Pharmacy
Ipswich, , United Kingdom
Kidderminster Hospital; Oncology Dept
Kidderminster, , United Kingdom
Royal Free Hospital; Dept of Oncology
London, , United Kingdom
Guys Hosp./Med. Onc./3rd Fl. T; Clinical Trial Office
London, , United Kingdom
Queen Elizabeth Hospital
London, , United Kingdom
Macclesfield District General Hospital
Macclesfield, , United Kingdom
Maidstone & Tonbridge Wells Hospital; Kent Oncology Center
Maidstone, , United Kingdom
The James Cook University Hospital
Middlesbrough, , United Kingdom
Freeman Hospital
Newcastle upon Tyne, , United Kingdom
North Tyneside General Hospital
North Shields, , United Kingdom
Mount Vernon Cancer Centre
Northwood, , United Kingdom
Nottingham University Hospitals City Campus
Nottingham, , United Kingdom
Peterborough City Hospital, Edith Cavell Campus; Oncology Department
Peterborough, , United Kingdom
Derriford Hospital; Gastroenterology
Plymouth, , United Kingdom
Queen's Hospital
Romford, , United Kingdom
Scunthorpe General Hospital; Dept of Oncology
Scunthorpe, , United Kingdom
Stafford Hospital; Oncology Department
Stafford, , United Kingdom
The Royal Marsden Hospital
Sutton, , United Kingdom
Great Western Hospital, Swindon Cancer Research Unit; Osprey Unit Level 3
Swindon, , United Kingdom
Torbay Hospital; Oncology
Torquay, , United Kingdom
Royal Cornwall Hospital; Dept of Clinical Oncology
Truro, , United Kingdom
Walsall Manor Hospital
Walsall, , United Kingdom
Royal Hampshire County Hospital; Winchester & Andover Breast Unit
Winchester, , United Kingdom
The Royal Wolverhampton Hospitals NHS Trust
Wolverhampton, , United Kingdom
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Khakoo S, Chau I, Pedley I, Ellis R, Steward W, Harrison M, Baijal S, Tahir S, Ross P, Raouf S, Ograbek A, Cunningham D; ACORN investigators. ACORN: Observational Study of Bevacizumab in Combination With First-Line Chemotherapy for Treatment of Metastatic Colorectal Cancer in the UK. Clin Colorectal Cancer. 2019 Dec;18(4):280-291.e5. doi: 10.1016/j.clcc.2019.07.003. Epub 2019 Jul 11.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
ML27971
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.